Literature DB >> 11461707

Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses.

S Y Chan1, C J Empig, F J Welte, R F Speck, A Schmaljohn, J F Kreisberg, M A Goldsmith.   

Abstract

Human infections by Marburg (MBG) and Ebola (EBO) viruses result in lethal hemorrhagic fever. To identify cellular entry factors employed by MBG virus, noninfectible cells transduced with an expression library were challenged with a selectable pseudotype virus packaged by MBG glycoproteins (GP). A cDNA encoding the folate receptor-alpha (FR-alpha) was recovered from cells exhibiting reconstitution of viral entry. A FR-alpha cDNA was recovered in a similar strategy employing EBO pseudotypes. FR-alpha expression in Jurkat cells facilitated MBG or EBO entry, and FR-blocking reagents inhibited infection by MBG or EBO. Finally, FR-alpha bound cells expressing MBG or EBO GP and mediated syncytia formation triggered by MBG GP. Thus, FR-alpha is a significant cofactor for cellular entry for MBG and EBO viruses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461707     DOI: 10.1016/s0092-8674(01)00418-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  79 in total

1.  Rafts promote assembly and atypical targeting of a nonenveloped virus, rotavirus, in Caco-2 cells.

Authors:  Catherine Sapin; Odile Colard; Olivier Delmas; Cedric Tessier; Michelyne Breton; Vincent Enouf; Serge Chwetzoff; Jocelyne Ouanich; Jean Cohen; Claude Wolf; Germain Trugnan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection.

Authors:  Graham Simmons; Andrew J Rennekamp; Ning Chai; Luk H Vandenberghe; James L Riley; Paul Bates
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.

Authors:  Carmen P Alvarez; Fátima Lasala; Jaime Carrillo; Oscar Muñiz; Angel L Corbí; Rafael Delgado
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 5.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

Review 6.  Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus.

Authors:  Diky Mudhakir; Hideyoshi Harashima
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

Review 7.  Ebola virus pathogenesis: implications for vaccines and therapies.

Authors:  Nancy Sullivan; Zhi-Yong Yang; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 8.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

9.  Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events.

Authors:  Melinda A Brindley; Laura Hughes; Autumn Ruiz; Paul B McCray; Anthony Sanchez; David A Sanders; Wendy Maury
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

10.  Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity.

Authors:  Chantelle L Hood; Jonathan Abraham; Jeffrey C Boyington; Kwanyee Leung; Peter D Kwong; Gary J Nabel
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.